Private Credit for GCC Healthcare Platforms: Claims, Clinicians and Expansion Capex

A Growth-Debt Framework for Claims Conversion, Practitioner Continuity, Site Ramp-Up, Equipment Value and Covenant Headroom

Authored by Chennakeshav Adya, Independent Researcher

August 2026

Abstract

Healthcare platforms across the Gulf Cooperation Council can require debt for working capital, clinic or hospital expansion, diagnostic equipment, technology, acquisitions and shareholder liquidity. Their repayment capacity depends on more than reported EBITDA. Care is delivered before many insurers, third-party administrators or government programmes pay. Revenue can depend on scarce clinicians. New sites consume cash before patient volume and claims collections mature. Medical equipment can be essential to operations while carrying specialised resale, maintenance and technology risk.

The region's digital claims infrastructure makes these states increasingly observable. Dubai's eClaimLink publishes standard data sets, payer and provider lists, coding references and denial codes.[1] Abu Dhabi's Department of Health claims adjudication standard defines full settlement, partial settlement and dismissal and requires traceable adjudication rules.[2] Its medical-billing standard covers eligibility, coding, submission, resubmission, reconciliation and follow-up.[3] Saudi Arabia's NPHIES platform defines eligibility, pre-authorisation, claims, re-adjudication, payment notification and payment confirmation transactions and groups more than 80 denial codes across benefit, clinical and operational categories.[4] These systems create structured evidence. They do not make every submitted claim collectible.

This paper develops a private-credit framework for financing a GCC healthcare platform. It constructs a claims cash curve, clinician dependency map, site ramp model, equipment collateral table and covenant-headroom dashboard. It shows how a lender can separate working-capital, equipment and growth uses; reconcile clinical and billing evidence to collections; calibrate debt against mature-site cash; release delayed-draw capital against operating milestones; and preserve liquidity when a payer slows, a clinician leaves or a new site underperforms.

Every claim amount, clinician count, retention rate, site volume, margin, equipment value, denial rate, advance rate, reserve, facility size, interest rate, covenant and timing assumption in the worked examples is a hypothetical modelling assumption created solely to demonstrate the method. The examples do not describe an identified provider, clinician, payer, lender, financing, forecast, valuation or investment recommendation. Actual financeability depends on current law and regulation, executed contracts, claim-level evidence, licensing, clinical quality, data protection, employment, tax, accounting, insolvency, security, equipment, financing terms and credit approval.

JEL Classification: G21, G23, G28, G32, I11, I13, J44

Keywords: GCC healthcare, private credit, growth debt, medical claims, clinician retention, site ramp-up, equipment finance, borrowing base, covenants, healthcare platform

1. Define the healthcare platform before financing it

A healthcare platform combines licensed entities, facilities, clinicians, equipment, patient demand, payer contracts, claims, technology and working capital. The lender should identify which entity owns each asset, holds each licence, employs or contracts each practitioner, bills each payer and receives each cash flow. Consolidated accounts do not provide that map.

The financing purpose should be divided into operating working capital, equipment, fit-out, acquisition consideration, new-site ramp and general corporate uses. Each use has a different cash life and control. A receivables revolver can fund the delay between care and collection. Equipment can support amortising debt aligned with useful life. A delayed-draw growth tranche can fund sites after licensing, lease, equity and operating milestones. Acquisition debt depends on the target's sustainable cash and integration plan.

The claim should be traced from patient registration, eligibility confirmation and authorisation through encounter documentation, diagnosis and procedure coding, tariff application, claim submission, acknowledgement, adjudication, resubmission, reconciliation, payment notification and bank receipt. Each stage has a date, owner, system record and possible exception.

The legal debtor should be identified precisely. An insurer, third-party administrator, government programme, employer, patient or other sponsor can bear different portions of one encounter. A third-party administrator may process a claim without assuming ultimate payment risk. A payer group can contain several legal entities. The borrowing base should use the entity contractually responsible for payment.

The provider's right to payment should also be distinguished from expected reimbursement. A submitted claim can be incomplete, late, unauthorised, miscoded, priced above contract, duplicated or outside benefits. A claim acknowledged by an electronic platform is not necessarily admitted by the payer. A payment notification is stronger evidence than mere submission, while actual collection remains the strongest evidence for historical calibration.

Debt capacity should be based on cash that survives normal clinical operations, maintenance, recurring equipment replacement, leases, tax and working-capital needs. The model should distinguish mature facilities from ramping sites. It should also separate founder or clinician-related revenue that can continue from revenue whose continuity depends on one individual.

2. Map the full claim-to-cash cycle

The first diligence product should be a claim-to-cash map for each jurisdiction, payer, service line and system. It should show eligibility, pre-authorisation, encounter, documentation, coding, submission deadline, adjudication, denial response, resubmission, reconciliation, settlement and payment.

Dubai's eClaimLink provides standard data sets and lists for facilities, clinicians, payers, services, medicines and denial codes.[1] The presence of common fields and codes supports reconciliation across provider, payer and financing systems. The lender should still test whether the provider's source records populate the fields accurately and whether updates are implemented on time.

Abu Dhabi's adjudication standard describes automated simple and complex edits, provider access to adjudication guidelines and the payer decision between full settlement, partial settlement and dismissal.[2] The lender's data model should retain the reason, amount and date of each adjudication outcome. A net receivable cannot be reconstructed if the provider overwrites earlier claim versions.

Saudi NPHIES defines transactions for eligibility, authorisation, claims, re-adjudication, amendment, status inquiry, payment notification and confirmation.[4] It also distinguishes benefit, clinical and operational denial categories. This structure supports a state-based borrowing base in which advance rates can rise as a claim moves from submitted to accepted to scheduled for payment.

The map should include manual channels and exceptions. Government claims, overseas insurers, self-pay balances, package reconciliations and legacy contracts can sit outside the main exchange. Their evidence and payment behaviour should be analysed separately rather than assumed to follow the digital channel.

Table 1. Claim-state evidence and financing treatment

Claim state	Required evidence	Primary uncertainty	Indicative financing treatment	Monitoring field
care delivered	encounter, eligibility and clinical record	coverage, authorisation and coding incomplete	exclude	encounter date and responsible payer
coded and billable	completed documentation, codes and tariff	submission validity and contract edits	exclude or very low recognition	coding completion date
submitted	exchange acknowledgement and claim identifier	payer has not adjudicated	eligible only for proven low-denial pools with reserve	submission date and version
pending information	payer request and response deadline	documentation or data gap	exclude until cured	pending reason and aging
partially accepted	line-level adjudication and accepted amount	residual dispute and dilution	include accepted amount only	accepted amount and expected payment
denied, correctable	denial code, cure evidence and resubmission	cure success and time	exclude until re-accepted	denial root cause and resubmission date
denied, final	final rejection or expired appeal	no collectible value	exclude and write off	final disposition
payment notified	payer payment notification and reconciliation	timing, set-off or administrative delay	high eligibility subject to concentration	scheduled amount and date
collected	bank receipt allocated to claim	allocation and clawback	remove from base and apply cash waterfall	value date and account

Exact states and rights depend on the relevant payer contract and jurisdiction.

3. Build the claim-level data spine

A borrowing base requires a stable claim identifier that links the clinical event, billing record, payer response, general ledger and bank receipt. The lender should receive the claim history, not only the current balance.

Minimum data include provider entity, facility, patient pseudonymous identifier, payer, third-party administrator, policy or programme, service line, encounter date, authorisation, diagnosis, procedure, billed amount, contract amount, patient share, submission date, claim version, payer acknowledgement, adjudicated amount, denial code, resubmission, payment notification, cash receipt, credit note, write-off and dispute status.

Sensitive clinical and personal data should be minimised for financing. The lender needs enough information to validate claim existence, eligibility and performance without receiving unnecessary patient details. Data access, processing purpose, storage, transfer, retention, deletion and incident obligations should be documented under the applicable health and privacy regime.

The claim tape should reconcile to the accounts-receivable subledger, general ledger and audited or reviewed financial statements. Opening claims plus new billed claims minus collections, credits, write-offs and transfers should equal closing claims. Differences should be explained by claim versioning, patient-share reclassification, payer settlement or accounting cut-off.

Bank receipts should be allocated at claim or settlement-statement level. Unallocated cash can make the ledger appear older than economic reality or conceal that collections relate to claims outside the financed pool. A lender should require a dated allocation process and exception queue.

4. Construct the claims cash curve

Simple aging by invoice date can obscure where risk sits. A claims cash curve follows each monthly submission cohort through adjudication, acceptance and collection. The lender can then distinguish a slow but collectible payer from a disputed pool, and a mature facility from a new site whose billing operations are still stabilising.

Several clocks matter. Days from encounter to coding measure provider readiness. Days from coding to submission measure billing operations. Days from submission to first adjudication measure payer processing. Days from denial to resubmission measure cure discipline. Days from acceptance to payment measure settlement. Days from encounter to cash measure the complete working-capital cycle.

The borrowing base should choose a contractual and empirically useful aging start. Encounter date captures the full provider cycle but can penalise legitimate coding and submission periods. Submission date aligns with the payer claim but can reward delayed provider billing. A combined test can require both maximum encounter age and maximum submitted age.

Age buckets should be calibrated from claim-level liquidation. The lender should calculate how much of each historical cohort was eventually collected, diluted or written off and how long collection took. A ninety-day claim can remain strong under a slow government programme, while a ninety-day claim under a thirty-day insurer contract can signal dispute. The curve should be rebuilt by payer, facility, service line and claim state, then connected directly to the thirteen-week liquidity forecast.

Figure 1. Illustrative GCC healthcare claims cash curve



Hypothetical cohort-collection percentages demonstrate the method and are not observed provider data.

5. Map clinician dependency and continuity

Clinician dependency is a credit variable when one practitioner controls a meaningful share of revenue, referrals, clinical leadership, licence coverage or patient continuity. The platform should map each material clinician by facility, speciality, contract type, licence, revenue, direct contribution, patient cohort, referral source, notice period, restrictive covenant, succession depth and realistic replacement time.

Revenue attribution should avoid double counting. A surgeon may originate a case while anaesthesia, imaging, nursing and facility services create the billed amount. The platform should distinguish personally controlled demand from institutional demand and allocate contribution after consumables, clinician compensation, payer discounts and support costs.

Continuity should be evaluated through executed employment or services contracts, licence standing, incentive design, clinical-governance role, team depth and succession. A retention payment can protect continuity only when it is enforceable, affordable and aligned with patient care. Equity, deferred compensation or a transition payment should be modelled as cash uses rather than treated as free protection.

The departure scenario should model immediate volume loss, patient transfer, recruitment cost, credentialling and licensing lead time, locum cost, payer-panel approval and the claims lag of the replacement practitioner. A clinician may leave today while the cash effect appears over several months as existing claims collect and new encounters fall.

The lender should set a concentration threshold and a continuity action threshold. When one clinician exceeds the agreed share of contribution or a key contract enters its notice period, management should activate succession, retention or recruitment steps. Debt availability should reflect only actions supported by signed contracts and credible implementation evidence.

Figure 2. Illustrative clinician dependency map



Hypothetical contribution shares and replacement periods demonstrate concentration and continuity risk.

Table 2. Clinician continuity and credit treatment

Dependency factor	Required evidence	Credit concern	Financing treatment	Management action
revenue concentration	encounter, billing and contribution bridge	one clinician drives disproportionate cash	concentration overlay on debt capacity	diversify teams and referral channels
contract continuity	executed contract, notice and incentive terms	departure or renegotiation during debt tenor	require minimum remaining term or transition plan	renew early and align incentives
licence and payer panel	current licence and credentialling status	replacement cannot bill immediately	stress replacement delay and claims gap	maintain credentialling pipeline
clinical leadership	governance role and delegation matrix	quality or regulatory continuity weakens	condition expansion draw on successor coverage	name deputies and document protocols
patient continuity	repeat-patient and referral evidence	volume may follow practitioner	haircut personally controlled demand	institutionalise patient relationship
succession depth	roster, capacity and speciality coverage	no credible internal replacement	liquidity reserve or delayed expansion	train, recruit and cross-cover
restrictive obligations	covenant and enforceability review	practical protection differs by jurisdiction	credit only documented, advised protection	use transition and handover obligations
replacement economics	search, locum and compensation evidence	replacement cost compresses cash flow	include full replacement cost in downside	approved recruitment and locum plan

Hypothetical categories require platform-specific contracts, licensing evidence and contribution analysis.

6. Model site ramp-up by operating milestones

New clinics, hospitals and diagnostic sites should be financed through milestone-based draws. Lease execution and fit-out expenditure create no repayment capacity by themselves. The lender should track licensing, civil works, equipment delivery, information-system readiness, clinician recruitment, payer empanelment, opening, patient volume, clean-claim submission, collections and site contribution.

The ramp model should begin with weekly pre-opening cash and move to monthly operating cohorts. It should separate cash patients from insured patients because insured revenue can appear in the income statement before it reaches the bank. Patient volume, realised tariff, variable clinical cost, fixed staffing, rent, marketing and claims lag should be explicit.

Each draw should require the previous tranche's evidence and sufficient remaining equity. A fit-out draw can depend on certified progress. An equipment draw can depend on delivery, acceptance and insurance. An operating draw can depend on licence activation, clinicians, payer access and opening. Later draws should depend on volume, claims quality and liquidity rather than management forecasts alone.

Mature-site cash should remain visible. A platform can conceal a weak new site inside consolidated growth. Site-level contribution, working capital and debt service allow the lender to identify whether expansion is progressing, paused or consuming cash needed by established operations.

Figure 3. Illustrative healthcare site ramp model



Hypothetical monthly values demonstrate phased patient, claim and cash development.

7. Reconcile contractual price before applying an advance rate

Healthcare billing can begin with a list price and settle under a negotiated tariff, package, diagnostic-related group, discount, capitation rule or other arrangement. The lender should finance the contractual collectible amount rather than the provider's gross charge master.

The contract master should record payer, plan, facility, service, tariff, package, effective date, authorisation rule, filing deadline, payment period, audit, recoupment, dispute, set-off and termination. Changes should be version controlled. The billing system should apply the contract effective on the encounter date.

Packages need special care. Individual claim lines can be priced at zero within a package while the major code carries the price. Saudi NPHIES guidance refers to package pricing and standard code sets.[4] A line-level borrowing base should preserve the package relationship so that zero-priced components are not treated as missing revenue and the package is not double counted.

Retrospective discounts, volume rebates and settlement agreements create dilution. Historical dilution should be calculated as gross submitted less final cash, separated into contractual adjustment, denial, credit note, write-off and recoupment. A reserve should cover the higher of recent experience, stressed experience and known unresolved settlement exposure.

8. Test historical liquidation by cohort

Static-pool analysis follows a month of submitted claims until it is collected, diluted or written off. It avoids the distortion caused when new claims continually enter the ledger. Each cohort should be analysed by payer, facility and service line.

The lender should calculate cumulative cash at 30, 60, 90, 120, 180 and 270 days from submission. It should also calculate final dilution and unresolved balance. Recent cohorts can be compared at the same age with older cohorts. A deterioration in a sixty-day collection curve can trigger action before year-end aging appears abnormal.

Resubmission can reset system timestamps. The original submission date should remain available, and the borrowing base should prevent artificial rejuvenation. A claim that has been denied and resubmitted three times should not appear as a new thirty-day claim.

Seasonality should be tested around holidays, policy renewals, government budgets, medical peaks and payer settlement cycles. Acquisitions, new facilities and new payer contracts should form separate cohorts until sufficient evidence exists.

Table 3. Illustrative claim-cohort liquidation analysis

Submission cohort	Cash by day 30	Cash by day 60	Cash by day 90	Cash by day 180	Final dilution	Credit interpretation
established quarter 1	38%	66%	82%	94%	5%	reference performance
established quarter 2	36%	64%	81%	93%	6%	broadly stable
growth quarter 3	31%	57%	74%	89%	8%	slower adjudication and higher denial
new payer launch	22%	44%	63%	83%	11%	separate reserve and concentration cap
government programme	12%	31%	54%	88%	4%	slower but historically lower dilution
high-value inpatient	19%	42%	61%	80%	13%	package and authorisation review

Hypothetical percentages demonstrate same-age comparison.

9. Define eligible receivables precisely

Eligibility should be a claim-level rule applied consistently. The receivable must belong to an approved provider and payer, arise from a completed eligible service, have required eligibility and authorisation evidence, be coded and submitted within deadline, use the applicable contractual price, remain undisputed and fall within age and concentration limits.

Common exclusions include self-pay balances without proven collection, related-party claims, duplicate or late claims, final denials, missing documentation, unapproved services, suspended payer contracts, claims subject to fraud or material audit, credit balances, capitation outside the agreed treatment, restricted government claims and receivables already assigned or pledged.

Partial eligibility should be supported at claim-line level. If a payer accepts AED8,000 of a AED10,000 claim, the borrowing base should include no more than the accepted or empirically collectible portion. A top-down haircut applied to the total pool can conceal specific disputed claims.

Cross-border and multi-jurisdiction pools should be segregated. Assignment, notice, priority, data and enforcement differ. The UAE's Federal Decree-Law No. 16 of 2021 permits transfers of current and future receivables that are described sufficiently and establishes registration-based third-party effectiveness and priority.[7] Transaction counsel should confirm how those provisions apply to the provider, payer contract, notice and proposed security.

10. Build a growth-debt capital stack

The capital stack should match each use of funds to its cash life and evidence. A revolving receivables tranche can finance eligible claims. An amortising equipment tranche can follow supported useful life and conservative collateral value. A delayed-draw expansion tranche can fund certified fit-out and site milestones. Sponsor equity should absorb pre-opening risk, overruns and a defined share of ramp losses.

Facility size should be the minimum of several constraints: receivables availability, mature-site free cash flow, stressed fixed-charge coverage, equipment value, minimum liquidity, leverage and the committed facility limit. This prevents a large claim pool from supporting debt that the platform cannot service after recurring clinical operations and replacement capital expenditure.

Draw conditions should preserve purpose. Receivables proceeds should recycle as claims collect. Equipment debt should be paid directly against accepted invoices where feasible. Expansion debt should follow a board-approved site budget and an independent or lender-approved progress check. Acquisitions and shareholder distributions should require separate approval and a refreshed downside case.

Over-advances should be cured through cash retention, new eligible receivables or repayment within a short defined period. Cost overruns should be funded by equity before additional debt. A dispute, clinician departure, licensing delay or equipment acceptance failure should stop the affected draw immediately rather than wait for the next scheduled certificate.

Figure 4. Illustrative GCC healthcare platform growth-debt capital stack

EACH DEBT TRANCHE FOLLOWS A DIFFERENT CASH LIFE AND CONTROL



Hypothetical AED million amounts demonstrate matching of funding sources to uses.

Table 4. Illustrative medical-equipment collateral assessment

Equipment class	Gross cost (AEDm)	Indicative orderly value	Key value risks	Lender control
MRI system	12.0	45%	magnet condition, software, site removal, service history	serial number, title, maintenance and insurance
CT scanner	7.5	48%	tube life, software obsolescence, de-installation	acceptance certificate and service contract
laboratory automation	5.0	32%	reagent dependency, configuration, limited buyer pool	vendor rights and portability review
surgical platform	9.0	38%	consumables, licences, training and upgrade path	usage, service and transfer conditions
dental chairs and imaging	3.5	42%	fragmented units, installation and secondary demand	asset register and location control
fit-out and building systems	18.0	10%	landlord rights, removal cost and specialised use	lease consent and conservative value
general IT and furniture	4.0	15%	rapid obsolescence and dispersed assets	capped recognition or exclusion

Hypothetical values require independent inspection, title review and market evidence.

11. Value equipment as a separate collateral pool

Medical equipment can support amortising debt when title, location, condition, maintenance and realisable value are evidenced. The lender should not use accounting net book value as collateral value. Purchase price, remaining useful life and operational importance do not establish secondary-market proceeds.

The asset register should identify manufacturer, model, serial number, legal owner, facility, purchase date, invoice, acceptance, financing, warranty, maintenance, software, licence, calibration, insurance and lien. Imported equipment may involve vendor title retention or distribution restrictions. Installed equipment may require landlord consent and specialist de-installation.

Orderly liquidation value should reflect removal, shipping, recommissioning, software transfer, remaining tube or component life, regulatory approvals, service support and the depth of the buyer market. A highly productive machine can have modest collateral value if it is site-specific, expensive to move or dependent on non-transferable software.

Equipment debt tenor should remain inside supported useful life, with amortisation that preserves coverage as values fall. The facility should require maintenance, insurance, inspection and restrictions on relocation or disposal. Equipment proceeds should prepay the related tranche unless replacement is approved.

12. Create a cash-control and liquidity architecture

Collections should flow to a designated account subject to lender control or an agreed waterfall, depending on applicable law, contract and payer practice. Payer notices should identify the correct account and preserve patient and regulatory requirements.

The account structure should separate receivable proceeds from patient deposits, restricted government money, escrow, charity funds, VAT or tax liabilities and other amounts unavailable for debt service. A daily reconciliation should allocate receipts to settlement statements and claims.

The waterfall can first retain taxes, patient refunds or other agreed senior amounts, then cure any over-advance, pay interest and required amortisation, replenish reserves and release surplus to the provider while no trigger exists. During a trigger, surplus can remain trapped until the borrowing base and liquidity tests recover.

Payers can use set-off or recoupment against future payments. The lender should understand whether a controlled account captures gross collections before set-off and whether the payer can deduct across facilities, contracts or legal entities. The borrowing base should aggregate the corresponding exposure.

Figure 5. Illustrative healthcare platform covenant headroom dashboard



Hypothetical thresholds and forecast values demonstrate early-warning design.

13. Design covenant headroom before cash fails

Minimum liquidity and maximum utilisation should sit alongside claim metrics. Eligible receivables, advance rate, concentration and reserves define availability. Financial covenants should use cash available after recurring capital expenditure, taxes and required clinical operations.

Operational covenants can monitor encounter-to-submission days, clean-claim rate, first-pass acceptance, denial rate, resubmission time, collection days, unallocated cash and aged pending claims. Payer covenants can monitor concentration, termination, suspension, dispute and missed

settlement.

Data-quality covenants should cover missing identifiers, changed submission dates, unreconciled ledger differences and claim versions. A material reporting defect should stop new advances until corrected because the lender cannot calculate availability reliably.

Compliance covenants should require current provider licences, payer contracts, coding standards, data protection, fraud controls and prompt disclosure of regulatory correspondence, audits, recoupment notices and material patient complaints.

Table 5. Illustrative covenant and remedy ladder

Indicator	Early warning	Trigger	Immediate response	Escalated response
clean-claim submission	declines below recent range	below agreed floor	root-cause report and enhanced testing	reduce advance rate
denial and dilution	trend rises	exceeds reserve assumption	increase reserve and stop affected pool	independent review and repayment
aging	slower cohort liquidation	old balance exceeds cap	exclude excess and trap cash	mandatory amortisation
payer concentration	approaches limit	exceeds limit	exclude concentration excess	payer-specific reserve or new funding limit
submission timeliness	backlog increases	filing deadlines at risk	daily backlog plan	affected claims ineligible
data reconciliation	minor exceptions	material tape-to-ledger difference	suspend certificate	independent reconciliation
payer contract	adverse negotiation	termination or suspension	stop affected advances	mandatory prepayment from collections
licence or regulatory event	inquiry or audit	suspension, material sanction or invalid claim process	freeze draws and notify lender	restructure or enforce as documented
controlled account	allocation delay	diversion or unauthorised change	cash trap and cure	event of default where material

Definitions, thresholds, cure and materiality require transaction-specific drafting.

14. Stress payer delay, clinician loss and site underperformance together

Healthcare platform risks can compound. A documentation backlog increases denials, slows collections and consumes staff time. A payer dispute can coincide with a key clinician departure and the cash needs of a ramping site. A cyber incident can interrupt submission and bank allocation. A regulatory audit can create recoupment while new advances stop.

The downside model should combine higher denial, lower cure, longer adjudication, delayed settlement, clinician-related volume loss, replacement cost, site delay, equipment overrun, concentration haircut, recoupment and operating cost. It should show minimum liquidity, borrowing-base availability, over-advance, fixed-charge coverage and required management action by week and month.

The provider should identify essential clinical spending that cannot be cut without affecting care or licensing. Management action can reduce elective expansion, defer non-essential capital

expenditure, improve coding support, renegotiate suppliers or add equity. It should not assume unsafe clinical reductions.

Reverse stress testing should identify the denial and payment-delay combination that creates an over-advance or minimum-liquidity breach. The early-warning covenant should activate before that point.

The stress should also distinguish a delay from a loss. A reliable government or insurer balance can create severe liquidity pressure while remaining collectible. The facility can respond through lower availability, a dedicated slow-payer sublimit, longer tenor or more equity liquidity. A disputed balance with weak evidence requires an exclusion rather than extra time. This distinction prevents a lender from applying the same remedy to operational timing and fundamental collectability.

Management actions should be linked to claim operations. A temporary coding team can reduce an encounter backlog. Contract escalation can resolve repeated tariff errors. Clinical-documentation training can improve first-pass acceptance. Payer diversification takes longer and should not be credited before executed contracts and collected cohorts exist. Each action needs cost, owner, implementation date, evidence and forecast cash effect.

The lender should run a weekly thirteen-week liquidity forecast during a trigger. Collections should be drawn from claim-level expected dates and stressed by payer. Essential payroll, medicines, consumables, rent, tax and patient obligations should be shown separately. Availability should follow the recalculated pool, and any remaining gap should have a committed funding source or a defined reduction plan that preserves safe care.

15. Address recoupment and audit risk

Payers can review paid claims and seek recovery for duplicate, coding, documentation, benefit, fraud, misuse or other reasons under the relevant contract and rules. Abu Dhabi has published principles and procedures governing recovery of payment for healthcare services.[6] A lender financing collected claims still needs to consider future set-off against the remaining pool.

The provider should maintain audit notices, sampled claims, proposed findings, responses, final determinations, payment plans and set-offs. Exposure should be allocated by payer, facility, service line and period. Known amounts should be reserved in full where collection is probable and timing is near.

Historical recoupment should be included in dilution. Material open audits can justify a specific reserve or exclusion of the affected cohort. Fraud or misuse concerns can require a broader stop because they can affect payer relationships and regulatory standing beyond the sampled claims.

The financing documents should require prompt notice, information access and approval for material settlements where they affect collateral. The lender should avoid directing clinical or payer decisions and should preserve the provider's obligations to patients and regulators.

16. Separate mature-site cash from ramping-site needs

Mature sites should demonstrate recurring contribution after clinician compensation, occupancy, consumables, maintenance, technology, tax and replacement capital expenditure. Ramping sites should be measured separately until patient volume, claims quality and collections establish a reliable cash profile. Consolidated EBITDA can obscure that distinction.

The lender should require site-level revenue, contribution, claims, cash, staffing and capital expenditure. Management allocations should be transparent. Shared clinical, laboratory, technology and head-office costs should be allocated consistently so that apparent site profitability is not created by shifting expenses.

The operating model should identify the minimum cash needed to keep care and billing functioning at each site. Collections can lag for months after a disruption, and the borrowing base can decline immediately as new eligible claims fall. Minimum liquidity should cover essential payroll, medicines, consumables, maintenance, rent, patient obligations and claims operations.

Expansion should be paused when a site misses licensing, recruitment, claims-quality or liquidity milestones. The platform should preserve mature-site cash and committed equity before asking debt to fund a longer ramp. Any cross-support between legal entities should be documented and tested for regulatory, tax, minority, contractual and insolvency constraints.

17. Structure security and assignment carefully

The security package can include assignment or charge of eligible receivables, collection accounts, insurance proceeds, relevant contracts and shares or assets where lawful and appropriate. The exact package depends on the jurisdiction, provider licence, payer contract and financier status.

UAE receivables law recognises transfers of current and future receivables and uses registration for effectiveness against third parties and priority.[7] The CBUAE Finance Companies Regulation includes factoring within the regulated framework for finance companies.[8] Transaction counsel should confirm licensing, registration, notice, set-off, priority and enforcement.

Anti-assignment or consent provisions in payer contracts should be abstracted. Even where a transfer can be effective between transferor and transferee, payer defences, payment instructions and third-party priority need analysis. Government receivables may have additional restrictions.

Collateral descriptions should match claim data and legal entities. The lender should search for existing assignments, bank security, negative pledges and liens. Receivables already sold, pledged or subject to cash pooling should be excluded until priority is resolved.

18. Establish a controlled diligence path

The first fifteen days should map legal entities, facilities, licences, payers, administrators, claim systems, service lines, contracts, accounts and the proposed facility use. Management should deliver raw claim history, ledgers and bank receipts with data definitions.

Days sixteen to forty-five should reconcile claim cohorts, denial, aging, dilution, payer concentration, tariffs, recoupment and cash allocation. Samples should trace encounter evidence

to cash. Legal and regulatory advisers should review assignment, security, notice, data and provider obligations.

Days forty-six to seventy should build the borrowing base, reserves, downside, facility size, covenant package and cash waterfall. The provider should test a shadow certificate using the proposed definitions. Exceptions should be resolved or explicitly excluded.

Days seventy-one to ninety should finalise security, account control, payer notices where applicable, reporting, independent testing and closing conditions. The first post-closing certificate should be rehearsed before funding.

19. Use a credit committee gate that can say no

The credit paper should answer eight questions. Which legal payer owes each eligible claim? Which evidence establishes coverage, authorisation, coding, contract price and submission? How much was collected from comparable cohorts? Which denials are curable? How concentrated is the stressed pool? Which cash is restricted? How are assignment, account control and priority implemented? Which downside can the provider survive without harming care?

The facility should pause when claims cannot reconcile to cash, original submission dates are unavailable, payer identity is unclear, denial reasons are overwritten, provider licences or contracts are uncertain, patient or restricted money is counted as liquidity, assignment conflicts remain, or management cannot deliver a repeatable certificate.

The approval memorandum should list every management estimate, evidence gap, exclusion, reserve and condition. It should state which facts require a bring-down before closing and which milestones govern later availability.

Independent review should have a defined scope. Coding specialists can test sampled claims. Data reviewers can reproduce aging and cohorts. Legal advisers can review contracts and security. Finance reviewers can reconcile ledgers and cash. Management remains responsible for complete information and clinical compliance.

20. Turn the facility into a monthly operating discipline

The borrowing-base process can improve revenue-cycle management. A daily exception queue identifies missing eligibility, authorisation, documentation, coding and submission. A denial waterfall assigns root causes. A payer map directs contract and collection attention. A cash-control account forces timely allocation.

Finance, revenue cycle, clinical operations, coding, compliance and technology should own defined metrics. The monthly certificate should reconcile to the same source records used internally. Restatements should be visible and explained.

The lender should review leading indicators before availability falls. Encounter-to-submission time can signal future aging. First-pass acceptance can signal documentation quality. A rising pending-information queue can precede denial. Missed payment notifications can precede liquidity pressure.

A well-designed facility releases cash as claim evidence strengthens. It provides working-capital support while preserving payer, patient and regulatory obligations. It also gives management a

transparent route from care delivered to cash collected.

Conclusion

GCC healthcare platforms can support private credit when financing follows the legal and operational sources of repayment. Gross billed value is an initial record. Collectible value emerges through eligibility, authorisation, documentation, coding, contract pricing, submission, adjudication, reconciliation and settlement. Sustainable debt capacity also depends on clinician continuity, mature-site cash, controlled expansion and equipment value.

The framework in this paper combines a claims cash curve, clinician dependency map, site ramp model, equipment collateral assessment and covenant-headroom dashboard. It matches a receivables revolver, equipment tranche and delayed-draw growth debt to different uses, with sponsor equity absorbing pre-opening risk and overruns.

The result is a financing structure that can support working capital and expansion while protecting essential clinical operations. Providers gain liquidity and operating visibility. Lenders gain traceable claim evidence, defined milestones, conservative asset support and an actionable early-warning system.

References

[1] Dubai Health Authority. eClaimLink standard data sets, payer, provider, coding and denial-code resources, updated 2026. https://www.eclaimlink.ae/

[2] Department of Health Abu Dhabi. Health Insurance Claims Adjudication Standard. https://www.doh.gov.ae/-/media/Feature/Resources/Standards/HAAD_Health_Insurance_Claims_Adjudication_Standard.ashx

[3] Department of Health Abu Dhabi. Standard for Medical Billing Services in the Emirate of Abu Dhabi. https://www.doh.gov.ae/-/media/018EE04F272C4AD5876B5B9A36FAFCC4.ashx

[4] Council of Health Insurance, Saudi Arabia. NPHIES insurance services, transaction profiles, business rules and denial codes. https://chi.gov.sa/en/Uniplat/Pages/default3.aspx

[5] Council of Health Insurance, Saudi Arabia. Appendix 5, Provider Reconciliation. https://www.chi.gov.sa/en/knowledge-center/lawsregulations/Appendix%20%285%29%20provider%E2%80%99s%20reconcilement.pdf

[6] Department of Health Abu Dhabi. Standard for the Principles and Procedures Governing Recovery of Payment for Healthcare Services. https://www.doh.gov.ae/-/media/Feature/Resources/Standards/standardfortheprinciplesandproceduresgoverningtherecoveryofpaymentforhealthcareservicesunderthehealt.ashx

[7] United Arab Emirates. Federal Decree-Law No. 16 of 2021 on Factoring and Transfer of Receivables. https://www.uaelegislation.gov.ae/en/legislations/1515

[8] Central Bank of the UAE. Finance Companies Regulation, C 3/2023. https://rulebook.centralbank.ae/en/entiresection/5075

[9] Central Bank of the UAE. Legislation and related laws, including factoring and transfer of receivables. https://www.centralbank.ae/en/legislation/

[10] Council of Health Insurance, Saudi Arabia. Unified provider-insurer contract programme. https://www.chi.gov.sa/aboutchi/CCHIprograms/Pages/prog018.aspx

[11] Council of Health Insurance, Saudi Arabia. Reconciliation and Settlement Centre. https://www.chi.gov.sa/en/aboutchi/cchiprograms/pages/prog019.aspx

[12] Council of Health Insurance, Saudi Arabia. Regulation on qualification of health-insurance claims management companies. https://www.chi.gov.sa/

[13] National Health Information Center, Saudi Arabia. National Platform for Health and Insurance Information Exchange Services. https://nhic.gov.sa/nphies

[14] Department of Health Abu Dhabi. Healthcare Insurers Manual and policy resources. https://www.doh.gov.ae/en/resources/policies.aspx/en/term-of-use

[15] Dubai Health Authority. Standards for Telehealth Services, 2025. https://dha.gov.ae/uploads/012023/Standards%20for%20Telehealth%20Services2023158613.pdf

[16] Dubai Health Authority. Standards for Code of Ethics and Professional Conduct for Health Professionals, 2026. https://www.dha.gov.ae/uploads/012026/Standards%20for%20Code%20of%20Ethics%20and%20Professional%20Conduct%20for%20Health%20Professionals%20V1%20202613351.pdf

[17] World Health Organization. Global Health Expenditure Database. https://apps.who.int/nha/database

[18] World Bank. Private Participation in Infrastructure Database, health-sector project records. https://ppi.worldbank.org/en/ppi

[19] IFRS Foundation. IFRS 13 Fair Value Measurement. https://www.ifrs.org/issued-standards/list-of-standards/ifrs-13-fair-value-measurement/

[20] IFRS Foundation. IFRS 16 Leases. https://www.ifrs.org/issued-standards/list-of-standards/ifrs-16-leases/

About the Author

Chennakeshav (CK) is a corporate finance and investment banking executive with 25+ years of global experience in deal origination, structuring and execution across M&A, growth capital and corporate strategy. He has led value-creation mandates for founders, corporates and funds, bridging the boardroom view to hands-on execution and close.

His career spans Morgan Stanley, HSBC, Lloyds Banking Group, EWEC, ADQ portfolio companies and Emirates Growth Fund, across TMT, real estate, fintech, deeptech, cleantech, infrastructure and energy. He has partnered with C-suite leaders, private equity and venture funds, sovereign wealth funds and family offices to finance complex fund raises and scale-up ventures, and has led M&A due diligence, post-merger integration and business-transformation initiatives to create value.

At Matchpoint Partners he is Managing Partner, leading the firm's corporate finance, M&A and capital-raising practice. He holds an MBA from London Business School, an engineering degree from VTU and a Master of Laws (LLM, in progress) from UCL London.

An active start-up mentor, CK mentors at Techstars, DIFC FinTech Hive, Startup Grind, Founder Institute and IN5, serves as Entrepreneur Mentor in Residence (EMiR) at London Business School, and judges the Entrepreneurship World Cup.